Wiley Bros. Aintree Capital, LLC Gilead Sciences, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 61,014 shares of GILD stock, worth $5.63 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
61,014
Previous 25,735
137.09%
Holding current value
$5.63 Million
Previous $1.77 Million
189.75%
% of portfolio
0.1%
Previous 0.08%
Shares
5 transactions
Others Institutions Holding GILD
# of Institutions
1,925Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.7 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.07 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.71 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.56 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $116B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...